These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37004981)

  • 21. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
    Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib.
    Cole AL; Wood WA; Muluneh B; Lund JL; Elston Lafata J; Dusetzina SB
    JCO Oncol Pract; 2020 May; 16(5):e443-e455. PubMed ID: 32196424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population.
    Suprapti B; Andarsari MR; Hapsari PP; Khotib J; ; Bintoro SUY
    J Basic Clin Physiol Pharmacol; 2020 Aug; 31(5):. PubMed ID: 32764164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.
    Eghtedar A; Kantarjian H; Jabbour E; O'Brien S; Burton E; Garcia-Manero G; Verstovsek S; Ravandi F; Borthakur G; Konopleva M; Quintas-Cardama A; Cortes J
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):477-84. PubMed ID: 23770156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nilotinib in the treatment of chronic myeloid leukemia.
    Sacha T; Saglio G
    Future Oncol; 2019 Mar; 15(9):953-965. PubMed ID: 30547682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical Efficacy of Dasatinib, Nilotinib and Imatinib in Newly Diagnosed Patients with Chronic-Phase Chronic Myeloid Leukemia: A Three-year Retrospective Analysis].
    Wang YY; Zhao HG; Cui ZG; Li GL; Shi X; Xu H; Zhou Y; Zhao T
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):356-63. PubMed ID: 25948185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of Efficacy and Related Factors of Acquired Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with TKI].
    Jing Y; Yang L; Liu DH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1597-1604. PubMed ID: 29262882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Nilotinib treatment for patients with imatinib-resistant or intolerant chronic myeloid leukemia].
    Pan LQ; Liu WX; Zhu Y; Hong M; Qiao S; Li JY; Qian SX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1545-9. PubMed ID: 25543472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.
    Usuki K; Tojo A; Maeda Y; Kobayashi Y; Matsuda A; Ohyashiki K; Nakaseko C; Kawaguchi T; Tanaka H; Miyamura K; Miyazaki Y; Okamoto S; Oritani K; Okada M; Usui N; Nagai T; Amagasaki T; Wanajo A; Naoe T
    Int J Hematol; 2012 Apr; 95(4):409-19. PubMed ID: 22359103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
    Cerrano M; Crisà E; Pregno P; Aguzzi C; Riccomagno P; Boccadoro M; Ferrero D
    Am J Hematol; 2013 Oct; 88(10):838-42. PubMed ID: 23757199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
    Rea D; Nicolini FE; Tulliez M; Guilhot F; Guilhot J; Guerci-Bresler A; Gardembas M; Coiteux V; Guillerm G; Legros L; Etienne G; Pignon JM; Villemagne B; Escoffre-Barbe M; Ianotto JC; Charbonnier A; Johnson-Ansah H; Noel MP; Rousselot P; Mahon FX;
    Blood; 2017 Feb; 129(7):846-854. PubMed ID: 27932374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study.
    Malagola M; Iurlo A; Abruzzese E; Bonifacio M; Stagno F; Binotto G; D'Adda M; Lunghi M; Crugnola M; Ferrari ML; Lunghi F; Castagnetti F; Rosti G; Lemoli RM; Sancetta R; Coppi MR; Corsetti MT; Rege Cambrin G; Romano A; Tiribelli M; Russo Rossi A; Russo S; Aprile L; Bocchia M; Gandolfi L; Farina M; Bernardi S; Polverelli N; Roccaro AM; De Vivo A; Baccarani M; Russo D
    Cancer Med; 2021 Mar; 10(5):1726-1737. PubMed ID: 33594821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
    Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
    Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).
    Ishikawa J; Matsumura I; Kawaguchi T; Kuroda J; Nakamae H; Miyamoto T; Matsuoka KI; Shibayama H; Hino M; Hirase C; Kamimura T; Shimose T; Akashi K; Kanakura Y
    Int J Hematol; 2018 May; 107(5):535-540. PubMed ID: 29362980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Kurosawa H; Tanizawa A; Muramatsu H; Tono C; Watanabe A; Shima H; Ito M; Yuza Y; Hamamoto K; Hotta N; Okada M; Saito AM; Manabe A; Mizutani S; Adachi S; Horibe K; Ishii E; Shimada H
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27368. PubMed ID: 30084127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.
    Cortes JE; De Souza CA; Ayala M; Lopez JL; Bullorsky E; Shah S; Huang X; Babu KG; Abdulkadyrov K; de Oliveira JSR; Shen ZX; Sacha T; Bendit I; Liang Z; Owugah T; Szczudlo T; Khanna S; Fellague-Chebra R; le Coutre PD
    Lancet Haematol; 2016 Dec; 3(12):e581-e591. PubMed ID: 27890073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.